Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,483
archived clinical trials in
Influenza

Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
198
mi
from 43215
Bardstown, KY
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
198
mi
from 43215
Bardstown, KY
Click here to add this to my saved trials
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
394
mi
from 43215
Saint Louis, MO
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
394
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
762
mi
from 43215
Norfolk, NE
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
762
mi
from 43215
Norfolk, NE
Click here to add this to my saved trials
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
682
mi
from 43215
Omaha, NE
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
682
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
398
mi
from 43215
Binghamton, NY
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
398
mi
from 43215
Binghamton, NY
Click here to add this to my saved trials
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
720
mi
from 43215
Dakota Dunes, SD
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
720
mi
from 43215
Dakota Dunes, SD
Click here to add this to my saved trials
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
937
mi
from 43215
Fort Worth, TX
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
937
mi
from 43215
Fort Worth, TX
Click here to add this to my saved trials
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1136
mi
from 43215
San Angelo, TX
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1136
mi
from 43215
San Angelo, TX
Click here to add this to my saved trials
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
984
mi
from 43215
Tomball, TX
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
984
mi
from 43215
Tomball, TX
Click here to add this to my saved trials
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1513
mi
from 43215
Salt Lake City, UT
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1513
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1517
mi
from 43215
West Jordan, UT
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1517
mi
from 43215
West Jordan, UT
Click here to add this to my saved trials
Panblok H7 Vaccine Adjuvanted With AS03 or MF59
Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Panblok H7 Vaccine at Three Antigen Dose Levels Adjuvanted With AS03® or MF59®
Status: Enrolling
Updated:  12/31/1969
Johnson County Clin-Trials
629
mi
from 43215
Lenexa, KA
Panblok H7 Vaccine Adjuvanted With AS03 or MF59
Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Panblok H7 Vaccine at Three Antigen Dose Levels Adjuvanted With AS03® or MF59®
Status: Enrolling
Updated: 12/31/1969
Johnson County Clin-Trials
629
mi
from 43215
Lenexa, KA
Click here to add this to my saved trials
Panblok H7 Vaccine Adjuvanted With AS03 or MF59
Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Panblok H7 Vaccine at Three Antigen Dose Levels Adjuvanted With AS03® or MF59®
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associates, LLC
781
mi
from 43215
Wichita, KA
Panblok H7 Vaccine Adjuvanted With AS03 or MF59
Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Panblok H7 Vaccine at Three Antigen Dose Levels Adjuvanted With AS03® or MF59®
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associates, LLC
781
mi
from 43215
Wichita, KA
Click here to add this to my saved trials
Panblok H7 Vaccine Adjuvanted With AS03 or MF59
Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Panblok H7 Vaccine at Three Antigen Dose Levels Adjuvanted With AS03® or MF59®
Status: Enrolling
Updated:  12/31/1969
Central Kentucky Research Associates, Inc.
154
mi
from 43215
Lexington, KY
Panblok H7 Vaccine Adjuvanted With AS03 or MF59
Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Panblok H7 Vaccine at Three Antigen Dose Levels Adjuvanted With AS03® or MF59®
Status: Enrolling
Updated: 12/31/1969
Central Kentucky Research Associates, Inc.
154
mi
from 43215
Lexington, KY
Click here to add this to my saved trials
Panblok H7 Vaccine Adjuvanted With AS03 or MF59
Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Panblok H7 Vaccine at Three Antigen Dose Levels Adjuvanted With AS03® or MF59®
Status: Enrolling
Updated:  12/31/1969
Rochester Clinical Research Inc.
356
mi
from 43215
Rochester, NY
Panblok H7 Vaccine Adjuvanted With AS03 or MF59
Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Panblok H7 Vaccine at Three Antigen Dose Levels Adjuvanted With AS03® or MF59®
Status: Enrolling
Updated: 12/31/1969
Rochester Clinical Research Inc.
356
mi
from 43215
Rochester, NY
Click here to add this to my saved trials
Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)
A Phase 1/2, Randomized, Observer-Blinded, Active-Controlled Trials to Evaluate the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix-M1 Adjuvant (NanoFlu) in Healthy Older Adults
Status: Enrolling
Updated:  12/31/1969
Research Site US108
372
mi
from 43215
Raleigh, NC
Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)
A Phase 1/2, Randomized, Observer-Blinded, Active-Controlled Trials to Evaluate the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix-M1 Adjuvant (NanoFlu) in Healthy Older Adults
Status: Enrolling
Updated: 12/31/1969
Research Site US108
372
mi
from 43215
Raleigh, NC
Click here to add this to my saved trials
Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)
A Phase 1/2, Randomized, Observer-Blinded, Active-Controlled Trials to Evaluate the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix-M1 Adjuvant (NanoFlu) in Healthy Older Adults
Status: Enrolling
Updated:  12/31/1969
Research Site US106
398
mi
from 43215
Rocky Mount, NC
Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)
A Phase 1/2, Randomized, Observer-Blinded, Active-Controlled Trials to Evaluate the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix-M1 Adjuvant (NanoFlu) in Healthy Older Adults
Status: Enrolling
Updated: 12/31/1969
Research Site US106
398
mi
from 43215
Rocky Mount, NC
Click here to add this to my saved trials
Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)
A Phase 1/2, Randomized, Observer-Blinded, Active-Controlled Trials to Evaluate the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix-M1 Adjuvant (NanoFlu) in Healthy Older Adults
Status: Enrolling
Updated:  12/31/1969
Research Site US132
311
mi
from 43215
Statesville, NC
Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)
A Phase 1/2, Randomized, Observer-Blinded, Active-Controlled Trials to Evaluate the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix-M1 Adjuvant (NanoFlu) in Healthy Older Adults
Status: Enrolling
Updated: 12/31/1969
Research Site US132
311
mi
from 43215
Statesville, NC
Click here to add this to my saved trials
Centralized Reminder Recall - Flu RCT2
Centralized IIS-Based Reminder Recall to Increase Influenza Vaccination Rates in New York State - Second Trial in New York State
Status: Enrolling
Updated:  12/31/1969
University of California at Los Angeles
1982
mi
from 43215
Los Angeles, CA
Centralized Reminder Recall - Flu RCT2
Centralized IIS-Based Reminder Recall to Increase Influenza Vaccination Rates in New York State - Second Trial in New York State
Status: Enrolling
Updated: 12/31/1969
University of California at Los Angeles
1982
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
A Phase 1, Randomized, Controlled, Observer-blind Study to Assess the Reactogenicity, Safety, and Immunogenicity of a Live Attenuated Universal Influenza Vaccine (cH8/1N1 LAIV) Administered as a Single Priming Dose Followed Three Months Later by a Single Booster Dose of an Inactivated Universal Influenza Vaccine (cH5/1N1 IIV) (Adjuvanted With AS03A or Unadjuvanted) in 18 Through 39 Year-old Healthy Subjects, Contrasted With a Two Dose Schedule of an Inactivated Universal Influenza Vaccine (cH8/1N1 IIV + AS03A Followed Three Months Later by cH5/1N1 IIV + AS03A)
Status: Enrolling
Updated:  12/31/1969
Duke University
352
mi
from 43215
Durham, NC
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
A Phase 1, Randomized, Controlled, Observer-blind Study to Assess the Reactogenicity, Safety, and Immunogenicity of a Live Attenuated Universal Influenza Vaccine (cH8/1N1 LAIV) Administered as a Single Priming Dose Followed Three Months Later by a Single Booster Dose of an Inactivated Universal Influenza Vaccine (cH5/1N1 IIV) (Adjuvanted With AS03A or Unadjuvanted) in 18 Through 39 Year-old Healthy Subjects, Contrasted With a Two Dose Schedule of an Inactivated Universal Influenza Vaccine (cH8/1N1 IIV + AS03A Followed Three Months Later by cH5/1N1 IIV + AS03A)
Status: Enrolling
Updated: 12/31/1969
Duke University
352
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
A Phase 1, Randomized, Controlled, Observer-blind Study to Assess the Reactogenicity, Safety, and Immunogenicity of a Live Attenuated Universal Influenza Vaccine (cH8/1N1 LAIV) Administered as a Single Priming Dose Followed Three Months Later by a Single Booster Dose of an Inactivated Universal Influenza Vaccine (cH5/1N1 IIV) (Adjuvanted With AS03A or Unadjuvanted) in 18 Through 39 Year-old Healthy Subjects, Contrasted With a Two Dose Schedule of an Inactivated Universal Influenza Vaccine (cH8/1N1 IIV + AS03A Followed Three Months Later by cH5/1N1 IIV + AS03A)
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
97
mi
from 43215
Cincinnati, OH
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
A Phase 1, Randomized, Controlled, Observer-blind Study to Assess the Reactogenicity, Safety, and Immunogenicity of a Live Attenuated Universal Influenza Vaccine (cH8/1N1 LAIV) Administered as a Single Priming Dose Followed Three Months Later by a Single Booster Dose of an Inactivated Universal Influenza Vaccine (cH5/1N1 IIV) (Adjuvanted With AS03A or Unadjuvanted) in 18 Through 39 Year-old Healthy Subjects, Contrasted With a Two Dose Schedule of an Inactivated Universal Influenza Vaccine (cH8/1N1 IIV + AS03A Followed Three Months Later by cH5/1N1 IIV + AS03A)
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
97
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Genetic and Environmental Factors in the Response to Influenza Vaccination
Genetic and Environmental Factors in the Response to Influenza Vaccination
Status: Enrolling
Updated:  12/31/1969
Stanford University
2100
mi
from 43215
Stanford, CA
Genetic and Environmental Factors in the Response to Influenza Vaccination
Genetic and Environmental Factors in the Response to Influenza Vaccination
Status: Enrolling
Updated: 12/31/1969
Stanford University
2100
mi
from 43215
Stanford, CA
Click here to add this to my saved trials
Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)
Adaptive and Innate Immunity, Memory and Repertoire in Vaccination and Infection
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
2100
mi
from 43215
Stanford, CA
Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)
Adaptive and Innate Immunity, Memory and Repertoire in Vaccination and Infection
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
2100
mi
from 43215
Stanford, CA
Click here to add this to my saved trials
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
A Study to Investigate the Incidence of Influenza and Influenza-related Complications, in Adults Between 50-64 Years and Elderly Adults 65 Years and Over Vaccinated With Fluarix™
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
699
mi
from 43215
Mobile, AL
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
A Study to Investigate the Incidence of Influenza and Influenza-related Complications, in Adults Between 50-64 Years and Elderly Adults 65 Years and Over Vaccinated With Fluarix™
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
699
mi
from 43215
Mobile, AL
Click here to add this to my saved trials
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
A Study to Investigate the Incidence of Influenza and Influenza-related Complications, in Adults Between 50-64 Years and Elderly Adults 65 Years and Over Vaccinated With Fluarix™
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
948
mi
from 43215
Delray Beach, FL
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
A Study to Investigate the Incidence of Influenza and Influenza-related Complications, in Adults Between 50-64 Years and Elderly Adults 65 Years and Over Vaccinated With Fluarix™
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
948
mi
from 43215
Delray Beach, FL
Click here to add this to my saved trials
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
A Study to Investigate the Incidence of Influenza and Influenza-related Complications, in Adults Between 50-64 Years and Elderly Adults 65 Years and Over Vaccinated With Fluarix™
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
975
mi
from 43215
Pembroke Pines, FL
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
A Study to Investigate the Incidence of Influenza and Influenza-related Complications, in Adults Between 50-64 Years and Elderly Adults 65 Years and Over Vaccinated With Fluarix™
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
975
mi
from 43215
Pembroke Pines, FL
Click here to add this to my saved trials
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
A Study to Investigate the Incidence of Influenza and Influenza-related Complications, in Adults Between 50-64 Years and Elderly Adults 65 Years and Over Vaccinated With Fluarix™
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1759
mi
from 43215
Las Vegas, NV
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
A Study to Investigate the Incidence of Influenza and Influenza-related Complications, in Adults Between 50-64 Years and Elderly Adults 65 Years and Over Vaccinated With Fluarix™
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1759
mi
from 43215
Las Vegas, NV
Click here to add this to my saved trials
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
A Study to Investigate the Incidence of Influenza and Influenza-related Complications, in Adults Between 50-64 Years and Elderly Adults 65 Years and Over Vaccinated With Fluarix™
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
450
mi
from 43215
Somers Point, NJ
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
A Study to Investigate the Incidence of Influenza and Influenza-related Complications, in Adults Between 50-64 Years and Elderly Adults 65 Years and Over Vaccinated With Fluarix™
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
450
mi
from 43215
Somers Point, NJ
Click here to add this to my saved trials
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
A Study to Investigate the Incidence of Influenza and Influenza-related Complications, in Adults Between 50-64 Years and Elderly Adults 65 Years and Over Vaccinated With Fluarix™
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
407
mi
from 43215
Camillus, NY
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
A Study to Investigate the Incidence of Influenza and Influenza-related Complications, in Adults Between 50-64 Years and Elderly Adults 65 Years and Over Vaccinated With Fluarix™
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
407
mi
from 43215
Camillus, NY
Click here to add this to my saved trials
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
A Study to Investigate the Incidence of Influenza and Influenza-related Complications, in Adults Between 50-64 Years and Elderly Adults 65 Years and Over Vaccinated With Fluarix™
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
366
mi
from 43215
Raleigh, NC
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
A Study to Investigate the Incidence of Influenza and Influenza-related Complications, in Adults Between 50-64 Years and Elderly Adults 65 Years and Over Vaccinated With Fluarix™
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
366
mi
from 43215
Raleigh, NC
Click here to add this to my saved trials
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
A Study to Investigate the Incidence of Influenza and Influenza-related Complications, in Adults Between 50-64 Years and Elderly Adults 65 Years and Over Vaccinated With Fluarix™
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
165
mi
from 43215
Pittsburgh, PA
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
A Study to Investigate the Incidence of Influenza and Influenza-related Complications, in Adults Between 50-64 Years and Elderly Adults 65 Years and Over Vaccinated With Fluarix™
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
165
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
A Study to Investigate the Incidence of Influenza and Influenza-related Complications, in Adults Between 50-64 Years and Elderly Adults 65 Years and Over Vaccinated With Fluarix™
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
426
mi
from 43215
Norfolk, VA
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
A Study to Investigate the Incidence of Influenza and Influenza-related Complications, in Adults Between 50-64 Years and Elderly Adults 65 Years and Over Vaccinated With Fluarix™
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
426
mi
from 43215
Norfolk, VA
Click here to add this to my saved trials
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
A Study to Investigate the Incidence of Influenza and Influenza-related Complications, in Adults Between 50-64 Years and Elderly Adults 65 Years and Over Vaccinated With Fluarix™
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from 43215
Gueglingen,
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
A Study to Investigate the Incidence of Influenza and Influenza-related Complications, in Adults Between 50-64 Years and Elderly Adults 65 Years and Over Vaccinated With Fluarix™
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from 43215
Gueglingen,
Click here to add this to my saved trials
Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza
Monitoring Influenza Severity on Tamiflu (MIST)
Status: Enrolling
Updated:  12/31/1969
Marshfield Clinic Research Foundation
488
mi
from 43215
Marshfield, WI
Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza
Monitoring Influenza Severity on Tamiflu (MIST)
Status: Enrolling
Updated: 12/31/1969
Marshfield Clinic Research Foundation
488
mi
from 43215
Marshfield, WI
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2017-2018 Formulations
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 021
678
mi
from 43215
Council Bluffs, IA
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2017-2018 Formulations
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 021
678
mi
from 43215
Council Bluffs, IA
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2017-2018 Formulations
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 012
198
mi
from 43215
Bardstown, KY
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2017-2018 Formulations
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 012
198
mi
from 43215
Bardstown, KY
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2017-2018 Formulations
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 018
798
mi
from 43215
Metairie, LA
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2017-2018 Formulations
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 018
798
mi
from 43215
Metairie, LA
Click here to add this to my saved trials
Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly
A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without AS03 Adjuvant
Status: Enrolling
Updated:  12/31/1969
Emory Vaccine Center - The Hope Clinic
433
mi
from 43215
Decatur, GA
Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly
A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without AS03 Adjuvant
Status: Enrolling
Updated: 12/31/1969
Emory Vaccine Center - The Hope Clinic
433
mi
from 43215
Decatur, GA
Click here to add this to my saved trials
Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly
A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without AS03 Adjuvant
Status: Enrolling
Updated:  12/31/1969
University of Iowa - Vaccine Research & Education Unit
460
mi
from 43215
Iowa City, IA
Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly
A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without AS03 Adjuvant
Status: Enrolling
Updated: 12/31/1969
University of Iowa - Vaccine Research & Education Unit
460
mi
from 43215
Iowa City, IA
Click here to add this to my saved trials
Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly
A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without AS03 Adjuvant
Status: Enrolling
Updated:  12/31/1969
University of Maryland School of Medicine - Center for Vaccine Development - Baltimore
344
mi
from 43215
Baltimore, MD
Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly
A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without AS03 Adjuvant
Status: Enrolling
Updated: 12/31/1969
University of Maryland School of Medicine - Center for Vaccine Development - Baltimore
344
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly
A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without AS03 Adjuvant
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases
2006
mi
from 43215
Seattle, WA
Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly
A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without AS03 Adjuvant
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases
2006
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly
A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without AS03 Adjuvant
Status: Enrolling
Updated:  12/31/1969
Duke Human Vaccine Institute - Duke Vaccine and Trials Unit
354
mi
from 43215
Durham, NC
Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly
A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without AS03 Adjuvant
Status: Enrolling
Updated: 12/31/1969
Duke Human Vaccine Institute - Duke Vaccine and Trials Unit
354
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort
Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort
Status: Enrolling
Updated:  12/31/1969
Stanford LPCH Vaccine Program
2101
mi
from 43215
Stanford, CA
Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort
Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort
Status: Enrolling
Updated: 12/31/1969
Stanford LPCH Vaccine Program
2101
mi
from 43215
Stanford, CA
Click here to add this to my saved trials
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above
Status: Enrolling
Updated:  12/31/1969
Coastal Clinical Research Inc
703
mi
from 43215
Mobile, AL
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above
Status: Enrolling
Updated: 12/31/1969
Coastal Clinical Research Inc
703
mi
from 43215
Mobile, AL
Click here to add this to my saved trials
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above
Status: Enrolling
Updated:  12/31/1969
Anaheim Clinical Trials, LLC
1960
mi
from 43215
Anaheim, CA
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above
Status: Enrolling
Updated: 12/31/1969
Anaheim Clinical Trials, LLC
1960
mi
from 43215
Anaheim, CA
Click here to add this to my saved trials
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above
Status: Enrolling
Updated:  12/31/1969
Paradigm clinical Research Centers, Inc
2059
mi
from 43215
Redding, CA
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above
Status: Enrolling
Updated: 12/31/1969
Paradigm clinical Research Centers, Inc
2059
mi
from 43215
Redding, CA
Click here to add this to my saved trials
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above
Status: Enrolling
Updated:  12/31/1969
Clinical Research of South Florida, an AMR Company
994
mi
from 43215
Coral Gables, FL
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above
Status: Enrolling
Updated: 12/31/1969
Clinical Research of South Florida, an AMR Company
994
mi
from 43215
Coral Gables, FL
Click here to add this to my saved trials
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above
Status: Enrolling
Updated:  12/31/1969
Meridan Clinical Research, LLC
560
mi
from 43215
Savannah, GA
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above
Status: Enrolling
Updated: 12/31/1969
Meridan Clinical Research, LLC
560
mi
from 43215
Savannah, GA
Click here to add this to my saved trials
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research, Inc.
1725
mi
from 43215
Meridian, ID
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research, Inc.
1725
mi
from 43215
Meridian, ID
Click here to add this to my saved trials
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above
Status: Enrolling
Updated:  12/31/1969
Johnson County Clin-Trials
629
mi
from 43215
Lenexa, KA
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above
Status: Enrolling
Updated: 12/31/1969
Johnson County Clin-Trials
629
mi
from 43215
Lenexa, KA
Click here to add this to my saved trials